On probiotic integration in the management of inflammation and the maintenance of the intestinal epithelial barrier’s integrity
Accepted: May 28, 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Inflammatory bowel disease epidemiology has grown dramatically in recent years, particularly in developed and developing Western countries. Many factors, including stress, diet, and medications, cause and exacerbate inflammatory conditions. Inflammation is closely related to the concept of intestinal barrier integrity. When integrity is compromised, toxins and pathogens can enter the bloodstream. In recent years, there has been a growing interest in using probiotic bacteria to prevent or treat a variety of pathologies, including inflammatory bowel disease. Some studies have looked at the effectiveness of multi-strain probiotic supplements in preventing intestinal barrier dysfunction in in vitro models of lipopolysaccharide-induced inflammation. To mimic the intestinal barrier, human colon adenocarcinoma cell lines were established in Transwell co-culture models. The epithelium permeability was assessed by measuring the transepithelial electrical resistance. The expression of individual proteins involved in barrier function was assessed. The immunomodulatory effects of probiotic formulations were studied in both human macrophage cell lines and ex vivo human peripheral blood mononuclear cell-derived macrophages. The intestinal epithelial layer was also interfaced with a human mast cell line. Selected probiotics have demonstrated high potential for use in maintaining intestinal barrier integrity and possessing anti-inflammatory properties.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.